Recent posts

TypePostAuthorRepliesLast updated
PageAndrew S. Goldman, Counsel, Policy and Legal Affairs Claire Cassedy021 weeks 6 days ago
Blog entryNational Association of Manufacturers told USTR the EU position on LDC extension made a mockery of international trading system thiru022 weeks 2 days ago
Blog entryDifferences between the march-in, royalty free right, and government use options James Love022 weeks 3 days ago
Blog entry500+ Pages of Documents on NFL Attempts to Influence NIH Funding of Concussion Studies Zack Struver022 weeks 5 days ago
Blog entryNIH Waivers for U.S. Manufacturing Requirements for Federally-Funded Drugs Zack Struver022 weeks 6 days ago
Blog entryKEI Statement on United Nations Secretary-General's High-Level Panel on Access to Medicines Report KEI Staff023 weeks 2 days ago
Blog entryCancer Moonshot Blue Ribbon Panel Does Not Address Pricing, Alternative Funding Models Zack Struver023 weeks 2 days ago
Blog entrySummary of Report of United Nations Secretary-General's High-Level Panel on Access to Medicines Zack Struver023 weeks 3 days ago
Blog entryTRIPS Council (October 2014): India calls for de-linkage and innovation inducement prizes at WTO discussions on IP & innovation thiru023 weeks 4 days ago
Blog entryWIPO Marrakesh Treaty for the blind to come into force September 30, 2016, following ratification by Canada James Love024 weeks 2 days ago
Blog entryGerman Court Issues Compulsory License on HIV Drug Patent Andrew Goldman024 weeks 2 days ago
Blog entryCommentary on Hillary Clinton's Plan to Respond to Unjustified Price Hikes for Long-Available Drugs Claire Cassedy024 weeks 4 days ago
Blog entryKEI Briefing Note 2016:2: 2015-2016 Pharmaceutical Transparency Legislation Zack Struver024 weeks 5 days ago
Book pagePublications and Research Notes James Love024 weeks 5 days ago
Blog entry2016: KEI/MSF comments to NIH on licensing of patents on Attenuated Respiratory Syncytial Virus (RSV) Vaccines James Love026 weeks 2 days ago
Blog entryHarvoni & Sovaldi, Xtandi in Top 20 Costliest Medicare Drugs Zack Struver028 weeks 2 days ago
Blog entryBloomberg: CVS Will Exclude Xtandi From Formulary in 2017 Zack Struver029 weeks 5 days ago
Blog entryVivendi-SFR lobbyist nominated to WIPO Staff029 weeks 5 days ago
Blog entryProposal for a WTO Agreement on the Supply of Public goods KEI Staff030 weeks 2 days ago
Blog entryLetter from 56 non-profits and experts to Secretary of State John Kerry on pressure on global access to medicines initiatives Zack Struver030 weeks 4 days ago
Blog entryWIPO GA 2013 to decide on future of the Intergovernmental Committee on Genetic Resources, Traditional Knowledge and Folklore thiru030 weeks 4 days ago
Blog entryRoger Bate: Eclectic booster of corporate views thiru032 weeks 2 days ago
Blog entrySeptember 2004: TACD's Future of WIPO Conference thiru032 weeks 3 days ago
Blog entryFrancis Gurry appoints Sylvie Forbin, lobbyist for Vivendi, as new head of copyright at WIPO James Love032 weeks 4 days ago
Page2016: KEI comments on NIH proposal for exclusive licenses to Chimeron Bio Corporation Diane Singhroy032 weeks 5 days ago